Advanced Biologic Therapies
Escalation pathways for chronic wounds that haven't responded to standard care.
When standard care isn't enough.
Amniotic membranes and cellular tissue-based products (CTPs) are a critical next step for chronic wounds that have stalled. They deliver growth factors, extracellular matrix components, and anti-inflammatory properties directly to the wound bed.
GWA partners with manufacturers whose biologic platforms are designed for clinical utility, sterility standards, and reimbursement defensibility. We help your team pick the right product, train your staff, and get the documentation right.
- Amniotic membrane products for DFU and VLU escalation
- Multiple size options for precise wound coverage
- ISO-standard cleanroom processing
- 5-year shelf life options for inventory flexibility
- Documentation support aligned with LCD requirements
When to consider biologic therapy.
These are general indicators, not clinical directives. Escalation decisions depend on clinical judgment, payer requirements, and documented prior care.
Wound stalling after 4 weeks
When a wound fails to show measurable progress after 4 weeks of appropriate standard care.
Chronic inflammatory state
Persistent bioburden, chronic inflammation, or elevated protease activity that standard care can't resolve.
Diabetic foot ulcers
DFUs that don't achieve at least 50% area reduction after 4 weeks of standard care — consistent with most LCD requirements.
Venous leg ulcers
Chronic VLUs with inadequate response to compression therapy and standard wound care.
Documentation matters.
Defensible documentation is what makes biologic therapy programs sustainable. These practices support clinical accuracy, audit readiness, and reimbursement defensibility.
For educational purposes only. Reimbursement depends on patient-specific factors, payer policies, and documentation quality.
Common Questions
Need help building a biologic therapy program?
We can help you identify the right products, train your staff, and set up documentation workflows.